Enzo Biochem Inc. (NYSE:ENZ) today announced that its Enzo Clinical Labs
subsidiary and Massachusetts-based Nuclea Biotechnologies, Inc. have entered
into a non-exclusive distribution agreement to market Nuclea's non-invasive
HER-2/neu serum test, a key assay in the monitoring of metastatic breast
cancer.
This blood test facilitates the monitoring and treatment decisions of
women with metastatic breast cancer that overexpresses the HER-2/neu protein in
the tumor. Individuals with this condition tend to have a worse prognosis and a
more aggressive disease that can resist certain types of chemotherapy. The test
measures the portion of HER-2/neu protein that lies outside the surface of the
cell and being released into the blood stream, allowing for more informed
treatment decisions for a number of women who may not be responding to breast
cancer treatment or may be at risk for metastatic cancer and need revised
treatment plans.
"We are pleased to partner with Nuclea Biotechnologies in marketing
this key assay," said Cynthia Bowman, MD, Medical Director of Enzo
Clinical Labs. "Offering the serum HER2/neu testing ties in with our
expanding program of developing and making available high value esoteric
testing, especially in the area of women's health, and providing our physician
clients with yet another tool with which to customize a woman's assessment and
treatment. Moreover, the use of this assay in treatment monitoring may open up
our services to the Pharmaceutical market."
"Our agreement with Enzo will serve as a catalyst for greater
market reach of our serum HER-2/neu test," said Patrick Muraca, President
and CEO of Nuclea. "Enzo Labs' long standing reputation as a leader in the
delivery of high value diagnostics make them an excellent partner to increase
the market's recognition and use of this important breast cancer assay."
Utilizing the HER-2/neu blood test while monitoring the disease's
progression will enable physicians to better adapt, combine therapies and
change treatment protocols. Studies have demonstrated that use of combination
chemotherapy regimens provides a statistically significant advantage for
survival and tumor response in women with metastatic breast cancer.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and therapeutics through
the development of unique diagnostic platform technologies that provide
numerous advantages over previous standards. A global company, Enzo Biochem
utilizes cross-functional teams to develop and deploy products systems and
services that meet the ever-changing and rapidly growing needs of health care
both today and into the future. Underpinning Enzo Biochem's products and
technologies is a broad and deep intellectual property portfolio, with patent
coverage across a number of key enabling technologies.
About Nuclea Biotechnologies
Nuclea Biotechnologies, Inc. is headquartered in Pittsfield,
Massachusetts with additional operations in Worcester and Cambridge,
Massachusetts. Nuclea has developed and is commercializing unique diagnostic
tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also
performs research leading to novel molecular oncology companion diagnostics for
the pharmaceutical and biotechnology industries. http://www.nucleabio.com
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside of
the control of the company including, inter alia, the markets for the Company's
products and services, costs of goods and services, other expenses, government
regulations, litigations, and general business conditions. See Risk Factors in
the Company's Form 10-K for the fiscal year ended July 31, 2013. Investors are
cautioned that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations to
update any forward-looking statement as a result of developments occurring
after the date of this press release.
Source:
http://online.wsj.com/article/PR-CO-20140218-907495.html
No comments:
Post a Comment